CompletedPhase 2

Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient?

Sweden44 participantsStarted 2008-11

Plain-language summary

Graves thyrotoxicosis is a common autoimmune disease. Patients suffer at diagnosis from weight loss, increased heart rate and stress intolerance. Some patients have difficulties in regaining quality of life. Diagnosis is found through elevated thyroid hormones thyroxin, suppressed TSH (thyroid stimulating hormone) from the pituitary and elevated stimulatory antibodies, TRAb (thyrotropin receptor antibody) to the thyroid. Selenium is sparse in western Europe. This compound has important function in thyroid hormone metabolism and on the immune system. It is not known whether addition of selenium affects the well being of patients with Graves´thyrotoxicosis. The subject of this study is to investigate this

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * New diagnose of autoimmune thyrotoxicosis * biochemically proven with increased thyroxin * low TSH and elevated TRAb/or positive scintigraphy. * Age 18 - 55. Willing to participate - Exclusion Criteria: * No previous head trauma, * No difficulties with swedish language, * No medication which could affective neuropsychological testing, * No planned or ongoing pregnancies. * Normal intellectual capacity. * No severe ophthalmopathy, or other severe disease

What they're measuring

Effect on neuropsychological well-being

Timeframe: Inclusion going on until the end of 2011

Trial details

NCT IDNCT01247077

SponsorKarolinska Institutet

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-03

View on ClinicalTrials.gov More QoL Before and After 9 Month of Medical Treatment of Graves´Thyrotoxicosis trials